Dallas, TX (PRWEB) August 10, 2013
This report forecasts the Global Nanomedicine market to grow at a CAGR of 12.57 percent over the period 2012-2016. One of the key factors contributing to this market growth is the emergence of nanorobotics. The Global Nanomedicine market has also witnessed the increasing use of novel nanomaterials. However, lengthy approval procedures could pose a challenge to the growth of this market.
Get a copy of this report at http://www.rnrmarketresearch.com/global-nanomedicine-market-2012-2016-market-report.html.
This report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Nanomedicine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this space include Abbott Laboratories, AstraZeneca plc, Bristol-Myers Squibb Co., Celgene Corp., GlaxoSmithKline plc, and Pfizer Inc.
The other vendors mentioned in this report are Ablynx NV, Acusphere Inc., Aphios Corp., Arrowhead Research Corp., BioForce, Nanosciences Holdings Inc., Bio-Gate AG, Biophan Technologies Inc., BioSante Pharmaceuticals Inc., CombiMatrix Corp., Enzon Pharmaceuticals Inc., GE Healthcare Ltd., Gilead Sciences Inc., IDEX Corp., IGI Laboratories Inc., Kereos Inc., Kimberly-Clark Corp., MIV Therapeutics Inc., Nanobiotix S.A., NanoCarrier Co. Ltd., Nanogen Inc., NanoLogix Inc., NanoMed Pharmaceuticals Inc., Nanotherapeutics Inc., NanoViricides Inc., Paladin Labs Inc., pSivida Corp., Qiagen N.V., Roche Holding AG, Skyepharma PLC, Smith & Nephew plc, Starpharma Holdings Ltd., Stryker Corp., and Tecan Group Ltd
Copyright©2012 Vocus, Inc.
All rights reserved